Recent analyses have revealed that RUNX family members play important roles in both normal developmental processes and carcinogenesis. Of the three known RUNX family members, RUNX3 has been shown to be involved in neurogenesis of the dorsal root ganglia, T-cell differentiation and tumorigenesis of gastric epithelium. Deletion of the Runx3 locus in mice resulted in hyperplasia of the gastric epithelium due to the stimulation of proliferation and suppression of apoptosis that was accompanied by a reduced sensitivity to TGF-b1. In primary human gastric cancer specimens, RUNX3 is frequently inactivated by allele loss or gene silencing due to promoter hypermethylation. The tumorigenicity of human gastric cancer cell lines in nude mice decreased as the level of RUNX3 expression increased, which indicates that RUNX3 is a bona fide tumor suppressor of gastric cancers.
Introduction
Gastric cancers represent the second largest cause of cancer-related mortality worldwide and primarily afflict the East Asian population (Parkin et al., 1999) . Numerous genetic abnormalities associated with gastric cancer have been described. However, the molecular mechanisms underlying the pathogenesis have been characterized only recently. The Runt family of transcription factors consists of three members, RUNX1 (PEBP2aB/CBF2/AML1), RUNX2 (PEBP2aA/ CBFA1/AML3) and RUNX3 (PEBP2aC/CBFA3/ AML2). All three RUNXs play important roles in both normal developmental processes and carcinogenesis (Lund and van Lohuizen, 2002) . The RUNX1 locus, which is required for definitive hematopoiesis (Okuda et al., 1996; Wang et al., 1996; North et al., 1999; Yokomizo et al., 2001) , is the most frequent target of chromosome translocations in leukemia (Look, 1997) . RUNX2, which is essential for osteogenesis (Ducy et al., 1997; Komori et al., 1997; Otto et al., 1997) , is mutated in the human disease cleidocranial dysplasia (Lee et al., 1997; Mundlos et al., 1997) , an autosomal dominant bone disorder. RUNX3, on the other hand, is necessary for the suppression of cell proliferation of the gastric epithelium (Li et al., 2002) , neurogenesis of the dorsal root ganglia (Inoue et al., 2002; Levanon et al., 2002) and T-cell differentiation (Taniuchi et al., 2002; Woolf et al., 2003) . Primary gastric cancer specimens express significantly lower levels of RUNX3 due to a combination of a hemizygous deletion and hypermethylation of the RUNX3 promoter region (Li et al., 2002) . The gastric epithelium of RUNX3 knockout mice exhibits hyperplasia, a reduced rate of apoptosis and reduced sensitivity to TGF-b1, which suggests that the tumor suppressor activity of RUNX3 operates downstream of the TGF-b signaling pathway. Notably, the chromosome locus of RUNX3 (1p36) is among the most frequently affected regions in various types of cancers (Levanon et al., 1994; Bae et al., 1995; Weith et al., 1996) , which suggests that RUNX3 may be involved in these cancers as well. This review summarizes our current knowledge about the role of RUNX3 in malignancy. It also discusses possible mechanisms by which RUNX3 exerts its tumor suppressor activity.
RUNX3 in gastric cancer
To fully inactivate a tumor suppressor, at least two independent 'hits' are required. The attention in cancer research has typically been on two of the mechanisms that inactivate tumor suppressors, namely, intragenic mutations and loss of heterozygosity (LOH) or homozygous deletion. Chromosomal aberrations in gastric cancer have been studied extensively for the presence of these alterations and as a result the loss of many chromosomal loci has been discovered, including 1p, 5q, 7q, 12q, 17p and 18q (Sano et al., 1991; Uchino et al., 1992; Kuniyasu et al., 1994) . However, it remained unclear which are the genes that are specifically involved in gastric carcinogenesis, until recently. It was then found that DNA methylation is also a powerful mechanism that suppresses gene transcription, and as such represents an alternative mechanism of tumor suppressor inactivation in cancer. This led to the discovery that numerous tumor suppressor genes are hypermethylated on their promoter sequences in cancer cells. Genes that are inactivated by DNA methylation include RB, the von Hippel-Lindau gene (VHL),
), E-cadherin (E-cad), hMLH1, APC, RASSF1 and caspase-8 (Jones and Laird, 1999; Teitz et al., 2000; Brown and Strathdee, 2002) .
Recently, several lines of evidence have demonstrated that RUNX3 is a tumor suppressor of gastric cancer (Guo et al., 2002; Li et al., 2002) . RUNX3 is expressed in the gastrointestinal organs of the developing embryo and throughout the adulthood of the mouse. Based on the genomic structure of the RUNX family genes, RUNX3 is thought to be the most ancient form of the three mammalian RUNX genes (Bangsow et al., 2001) . Notably, Caenorhabditis elegans and the sea urchin contain only one RUNX gene, and these are expressed in the intestine and foregut, respectively (Bae and Lee, 2000; Nam et al., 2002; Robertson et al., 2002) . Since the gut is one of the most primitive organs, it may be that RUNX3 has played an important role in controlling the growth and differentiation of gut epithelial cells throughout evolution. Supporting this fact is that there is evidence that the RUNX homolog in both C. elegans and RUNX3 in the mouse participate in gut development. RNAi-mediated inhibition of the C. elegans RUNX homolog (Run) resulted in the malformation of the intestine (Nam et al., 2002) . Targeted inactivation of Runx3 in mice revealed in more detail the role that this gene plays in gut development. First, the gastric epithelium of Runx3À/À mice displayed hyperplasia due to an increase in cell proliferation and a reduced rate of apoptosis. Second, glandular stomach epithelial cell lines obtained from Runx3À/À mice on a p53À/À background are tumorigenic in nude mice, while the same cells from Runx3 þ / þ p53À/À mice are not (Li et al., 2002) . This indicates that Runx3 is involved in keeping cell proliferation under control, which is a typical feature of a tumor suppressor.
We investigated the potential connection between RUNX3 and gastric cancer by studying cell lines and primary human gastric tumors. Of 46 primary human gastric cancer specimens, 30% displayed hemizygosity of RUNX3. However, intragenic mutation in the remaining allele was very rare. Instead, this RUNX3 gene was silenced by DNA methylation. About 45-60% of the primary human gastric tumors analyzed exhibited reduced RUNX3 expression levels accompanied by hypermethylation of the CpG island located in the proximal (p2) promoter region (Li et al., 2002; Waki et al., 2003) . Interestingly, RUNX3 was also inactivated by DNA methylation in N-methyla-N-nitrosourea (MNU)-treated mice that developed gastric cancer (Guo et al., 2002) . In contrast, exogenous expression of RUNX3 in those murine gastric epithelial cells inhibited their growth in soft agar. Although the mechanism by which MNU induces gastric carcinomas remains unknown, it appears that Runx3 is one of the major targets of the carcinogen, since CpG islands in the Runx1 and Runx2 promoter regions were not methylated (Guo et al., 2002) , and Ras and p53 genes also do not appear to play important role (Furihata et al., 1997) .
Only one incidence of a mutation in RUNX3 was found in the 119 human tumors that were investigated.
This was a single-nucleotide transition within the conserved Runt domain that converted arginine 122 to cysteine (R122C). The identification of this single point mutation in a primary gastric tumor specimen significantly supports the notion that RUNX3 may act as a tumor suppressor (Li et al., 2002) . Moreover, when gastric cancer cells were transfected with RUNX3 followed by drug selection, only small numbers of G418-resistant foci formed, while cells transfected with RUNX3-R122C produced similar numbers of foci to those of vector-only control cells (Guo et al., 2002) . A tumorigenesis assay using nude mice revealed that RUNX3 significantly suppresses tumor growth and that the R122C point mutation of the gene found in a gastric cancer patient abolished this ability (Li et al., 2002) .
Collectively, these results provided strong evidence that RUNX3 is a tumor suppressor of gastric cancer and that inactivation of RUNX3 is causally associated with human gastric carcinogenesis.
Mechanisms underlying the tumor suppressor activity of RUNX3
The increased proliferation and decreased apoptosis of Runx3À/À gastric epithelial cells is accompanied by reduced sensitivity to TGF-b1, as TGF-b1-induced inhibition of proliferation was modestly affected in Runx3À/À gastric epithelial cells, while TGF-b1-induced apoptosis was strongly impaired. These results indicate that the tumor suppressor activity of RUNX3 is associated with the TGF-b signaling pathway. TGF-b receptors and its downstream signal transducer Smads are frequently inactivated in various cancers (Cohen, 2003) . p300, which transmits TGF-b signaling synergistically with Smads, is also mutated in several cancers (Gayther et al., 2000) . Notably, RUNX proteins physically interact with Smads and p300 and function synergistically (Kitabayashi et al., 1998; Hanai et al., 1999; Lee et al, 2000; Zhang et al., 2000) . The fact that Smad2, Smad4, p300 and RUNX3 all function as tumor suppressors (Ito and Miyazono, 2003) suggests that all these components are required for the tumor suppressor activity of the TGF-b signaling pathway.
TGF-b-mediated growth arrest occurs by blocking all cycle transits at mid-and late-G1 phases of the cell cycle (Weinberg, 1995; Sherr, 1996) . Generally, this arrest is temporary, but in some cases it is associated with terminal differentiation or programmed cell death. Two classes of antiproliferative gene responses are involved in the effect of TGF-b on growth arrest: inactivation of cyclin-dependent kinases (cdks) through the induction of cdk inhibitors, and downregulation of c-Myc, a proto-oncogene (Alexandrow and Moses, 1995) . The downregulation of c-Myc is required for the induction of p15 INK4B and p21 Cip (Warner et al., 1999; Claassen and Hann, 2000) . Since RUNX3 is required for the TGF-b1-induced inhibition of proliferation, RUNX3 may be involved in the TGF-b-mediated induction of CDK inhibitors and/or the Smad-mediated repression of the cMyc promoter.
TGF-b-induced apoptosis is a well-documented phenomenon that occurs in many different cell types (Schuster and Krieglstein, 2002) . The molecular mechanisms underlying the TGF-b-induced apoptosis of epithelial cells seem to involve the activation of Smad proteins. The overexpression of Smad4 induces apoptosis (Atfi et al., 1997) , while overexpression of a dominant-negative Smad3 mutant that impairs Smadmediated signal transduction inhibits TGF-b-dependent apoptosis (Yamamura et al., 2000) . Furthermore, the overexpression of JunD-FosB, which is known to interact with Smads (Zhang et al., 1998; Liberati et al., 1999) , potentiates TGF-b-mediated cell death. FosB substantially enhances Smad3-Smad4-dependent transcription, and dominant-negative FosB blocks TGF-b1-induced apoptosis, but not growth inhibition (Yamamura et al., 2000) . Several proapoptotic target genes regulated by the TGF-b signaling pathway have been identified (Schuster and Krieglstein, 2002) . For example, Bcl-2 and Bcl-xL are downregulated and Bax and zinc-finger transcription factor (TIEG) are upregulated (Teramoto et al., 1998; Chalaux et al., 1999; Chipuk et al., 2001) . However, the mechanisms that regulate the target genes remain to be resolved. Interestingly, RUNX2 interacts with AP-1 as well as Smads (Hanai et al., 1999; Hess et al., 2001) . If RUNX3 also interacts with AP-1, it may be that some of the target genes of the TGF-b signaling pathway are cooperatively regulated by Smads, AP-1 and RUNX3.
A large amount of research must be conducted before we can explain the full potential of RUNX3 as a tumor suppressor that should be tightly regulated during normal homeostasis of gastric epithelium.
Oncogenic potential of the RUNX transcription factors
Loss of function studies have supported the notion that the RUNX family proteins act as tumor suppressors in gastrointestinal carcinoma. However, the oncogenic potential of the RUNX family members in lymphomagenesis has also been observed in studies of CD2-Myc transgenic and murine leukemia virus (MLV)-infected mice. In these mice, c-Myc and Runx2 were upregulated and this resulted in a higher incidence of lymphomas (Stewart et al., 1997; Cameron et al., 2003) . In addition, Runx2 haploinsufficiency decreased the incidence of lymphomas in c-Myc/Runx2 transgenic or MLV-infected mice (Wotton et al., 2002) , which is a typical characteristic of proto-oncogenes. The analysis of CD2-Myc lymphomas for rearrangement of the Dsi1 locus revealed that Runx3 also is a target of virus insertion . Virus insertion at Runx3 locus has also been identified in T-cell lymphomas induced by the retrovirus SL3-3 (Kim et al., 2003) .
The Epstein-Barr virus (EBV) is a ubiquitous infectious agent that is carried by over 90% of the human population and is associated with B-cell lymphoma, mononucleosis and nasopharyngeal carcinoma (Kaiser et al., 1999) . In all, 5-10% of gastric cancers also contain the EBV genome (Imai et al., 1994 ). Burkitt's lymphoma (BL) cell lines with group I phenotype have a restricted expression pattern of EBV genes that is generally confined to EBNA1, whereas group III BL cells express additional genes including EBNA2. The analysis of B-cell lines revealed that RUNX3 expression is predominant in EBV latency III, whereas RUNX1 is associated with EBV latency I or EBV-negative cells (Spender et al., 2002) . Transformation of the group I BL cells that express RUNX1 occurs through the translocation of the c-Myc, so that it is constitutively expressed under the control of the immunoglobulin enhancer element. Interestingly, in the group III BL cells, the c-Myc gene is upregulated by EBNA2, which is absolutely essential for EBV-mediated immortalization (Hammerschmidt and Sugden, 1989; Kaiser et al., 1999) . Notably, EBNA-2 also induces RUNX3 expression (Spender et al., 2002) . Quiescent B cells initially express RUNX1, but 48 h after EBV infection, the level of RUNX1 decreases, whereas the RUNX3 expression increases dramatically. This class switch of RUNX by EBNA2 results in a greater abundance of total RUNX protein (Johannsen et al., 1995) . It remains to be determined whether the induction of both genes, cMyc and RUNX3, by EBNA2 contributes towards the induction of lymphomas.
It appears that both loss and gain of RUNX3 function can contribute to cancer development. This paradox has yet to be explained. However, it is worth mentioning that in order for normal cells to go through apoptosis upon TGF-b treatment, the c-Myc gene should be suppressed (Alexandrow and Moses, 1995) , while RUNX3 should be activated (Li et al., 2002) . Failure of the TGF-b-dependent downregulation of the c-Myc gene to occur is associated with breast cancer (Chen et al., 2001) . These results suggest that the oncogenic potential of RUNX3 is related to the level of c-Myc expression.
RUNX3 and chromosome locus 1p36
Since RUNX3 is an integral component of the TGF-binduced signaling pathway, it is possible that RUNX3 may also function as a tumor suppressor of other types of cancers where TGF-b signaling is impaired. Notably, the chromosome locus 1p36, which harbors RUNX3, is among the most frequently affected regions in various types of common cancers, including gastric cancer, colorectal cancer, prostate cancer, lung cancer, pancreatic cancer, bile duct cancer, bladder cancer, hepatocellular carcinoma and neuroblastoma (Weith et al., 1996) . Most of these cancers overlap with aberrant TGF-b signaling-associated cancers. The distal portion of mouse chromosome 4, which is syntenic with human chromosome band 1p36, is observed to undergo frequent deletion during experimentally induced carcinogenesis (Herzog et al., 1995) . Furthermore, introduction of a normal human chromosome 1p36 into colon carcinoma cells markedly suppressed their tumorigenicity (Tanaka et al., 1993) . Therefore, the 1p36 region is believed to harbor one or more tumor suppressor genes.
Evidence demonstrating that RUNX3 is a tumor suppressor of gastric cancer suggests that RUNX3 could be one of the elusive tumor suppressors that are postulated to reside at the locus that has long been of interest to cancer researchers. The reason why RUNX3
had not yet been identified as a tumor suppressor might be because this gene is inactivated mainly by epigenetic modification and genetic alteration of both alleles is very rare. In support of this speculation, the tumor suppressor locus of neuroblastoma has been mapped within a 300 kb region on 1p36. Around this region, nine genes were found to be expressed in neuroblastoma cells (Spieker et al., 2001) . RUNX3 is one of these genes. However, it is expressed only rarely in a subset of neuroblastoma cell lines and it showed no mutations. This result suggests that RUNX3 could be a tumor suppressor of neuroblastoma that is inactivated by LOH and DNA methylation. It has also been reported that RUNX3 is silenced in testicular yolk sac tumors by DNA methylation (Kato et al., 2003) . It would be particularly interesting to examine whether the inactivation of RUNX3 is associated with various types of cancers that are related to 1p36 deletion.
Perspectives
The role of RUNX3 as a tumor suppressor of gastric cancer has recently been elucidated. Physical interactions between RUNX3 and the components of the TGFb signaling pathway (which are known to be tumor suppressors), and the decreased sensitivity of Runx3À/À gastric epithelial cells to TGF-b1 indicate that the tumor suppressor activity of RUNX3 is associated with the TGF-b signaling pathway. However, the role RUNX3 plays in TGF-b-dependent cell cycle arrest and apoptosis is largely unclear. Since RUNX3 is a transcription factor, the identification of the target genes that are induced or suppressed by TGF-b-activated RUNX3 should provide important insights into the molecular mechanism behind its tumor suppressor activity.
In contrast to the classical tumor suppressors, in which both alleles are inactivated mainly by genetic alteration, RUNX3 is inactivated by DNA methylation, a reversible epigenetic modification. It is worth mentioning here that such tumor suppressor genes that are silenced by DNA methylation could be good drug targets because these genes are not permanently mutated and could be reactivated (Cameron et al., 1999; Jones and Laird, 1999) . This re-expression of epigenetically inactivated genes could suppress tumor growth or increase sensitization to other anticancer therapies. Some DNA methylase inhibitors and histone deacetylase inhibitors that reverse epigenetic inactivation are now undergoing clinical trials in cancer patients (Brown and Strathdee, 2002) . Further research into the mechanisms that regulate the tumor suppressor activity of RUNX3 and the possible involvement of RUNX3 in a variety of cancers apart from gastric cancers may illuminate a new objective in cancer treatment.
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